The newborn is an independent, officially-registered journal of the Global Newborn Society. We aim to be a prime source of information for the health of fetuses, neonates, and infants during the 1000 days after birth. Our published papers will encompass basic, translational, and clinical research including randomized trials, novel observational studies, and epidemiology. Basic science research will cover molecular biology, genetics, physiology, biochemistry, and pharmacology in fetal and neonatal life. Animal studies will be hypothesis-driven, and related to developmental processes or disorders in the human fetus or neonate. In addition to original research and reviews, we will also welcome consensus statements, guidelines, trials methodology, and core outcomes relevant to fetuses/young infants. 

 

A detailed set of guidelines for preparation and specific instructions to authors is provided in a following pages within this website. Correspondence regarding editorial matters, including suitability, should be addressed to the Editor-in-Chief. All manuscripts should be submitted to the Newborn via the online manuscript submission system. Authors will be notified of a decision by email within 2 weeks. 

​

All manuscripts must be written in English and adhere to the layout and length guidelines unless specifically approved by the Editor-in-Chief. Every issue will highlight Early Career Investigators (less than 7 years on faculty) and authors who do not use English as a first/second language and did most of the work in the article. The editorial board is currently discussing about the need and viability of versions of this journal in languages other than English. 

 

The newborn will not publish studies that duplicate existing information just to "confirm" the effectiveness of established therapies in "low- and middle-income countries (LMICs)", "low-resource settings", or in the "third world" unless there is a strong scientific rationale, an important sample size, or new methodology. However, we welcome statistically-robust projects focused on regionally-important genetic or other socio-economic factors that might affect the pathophysiology, treatment, and outcomes of various neonatal diseases.